CA-MCAFEE
24.7.2024 06:02:35 CEST | Business Wire | Press release
Today, McAfee Corp., a global leader in online protection, announced the extension of its ten-year partnership with Samsung, enabling enhanced protection for online threats to consumers’ privacy, identity and personal information.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723762355/en/
McAfee and Samsung Extend Partnership for 10th Year, Expand AI-Powered Online Protection for Samsung Customers Around the Globe via Galaxy Store (Photo: Business Wire)
Now, Samsung mobile devices, including the Galaxy S24 Ultra, Galaxy S24, Galaxy S24+, Galaxy Tab S9 series, Galaxy Z Flip6, and Galaxy Z Fold6, come with the Galaxy Store pre-installed. This is where users can download and use the McAfee Security app* that includes McAfee Scam Protection™, the company's patented AI technology that automatically identifies and alerts you if it detects a dangerous URL in your text messages. It also proactively blocks risky sites if you accidentally click on a scam link in a text, email, social media post, and more.
In addition to being available on consumer Galaxy phones and tablets, McAfee Security is now available for purchase for existing customers in 98 markets via the Galaxy Store. Consumers can easily buy and install the app on their Samsung mobile device, ensuring uninterrupted online protection. This is particularly important at a time when, with the rise of AI, cybercriminals are creating more convincing, personalized scams at scale, making it harder than ever for consumers to know what content to trust: 50% of mobile phone users say AI has made it harder for them to spot online scams and 39% of respondents admit to having clicked on text scam messages, such as a suspicious text from an unknown number or a fake package delivery text.**
These capabilities also help address key consumer concerns: according to McAfee’s recent Mobile Threat Survey, 90% of people globally are concerned about protecting their online privacy and identity when using their mobile phone. To further combat this concern in the age of AI, the latest Galaxy devices also come equipped with Advanced Intelligence settings***, giving users full control over how much they allow their data to enhance AI experiences by disabling online data processing.
"Our continued partnership with Samsung helps us do what matters most: protect more people so they can live their lives online with confidence," said Pedro Gutierrez, Senior Vice President at McAfee. "With the introduction of Samsung's new mobile AI experience and McAfee's continued focus on using AI to fight against AI scams, we’re thrilled to continue our partnership."
Samsung Galaxy devices, including the Galaxy S24 series, Galaxy Tab S9 series, Galaxy Z Flip6, and Galaxy Z Fold6, now offer McAfee Security with McAfee Scam Protection™ available at a special price through the pre-installed Galaxy Store app. This wide range of available devices with McAfee online protection solutions helps give users comprehensive protection against evolving online threats.
About McAfee
McAfee Corp. is a global leader in online protection for consumers. Focused on protecting people, not just devices, McAfee’s consumer solutions adapt to users’ needs in an always online world, empowering them to live securely through integrated, intuitive solutions that protect their families, communities, and businesses with the right security at the right moment. For more information, please visit https://www.mcafee.com.
_____________________________
* The McAfee Security app available in the Samsung Galaxy Store is McAfee Total Protection™ that includes McAfee Scam Protection, McAfee's patented and powerful Artificial Intelligence (AI) technology that protects against the surge in AI-generated phishing scams.
** McAfee Mobile Threat Survey February 2024 conducted by Market Research Company MSI-ACI with 4,032 adults from 7 countries including the United States, United Kingdom, France, Germany, Australia, India, and Japan.
*** Samsung Account login required. Advanced Intelligence settings preventing server access will limit the functionality of some AI features. Regardless of server access, Samsung does not save user input or output data. Different terms may apply for AI features provided by third parties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723762355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom